دورية أكاديمية

P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB

التفاصيل البيبلوغرافية
العنوان: P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB
المؤلفون: Nakamura, R., Hendricks, R., Dokhaei, R., Susilo, M., Wilson, D., Trudel, S., Cohen, A., Harrison, S. J., Krishnan, A., Fonseca, R., Adamkewicz, J. I., Li, M., Wong, C., Cooper, J., Sumiyoshi, T.
المصدر: HemaSphere ; volume 6, page 852-853 ; ISSN 2572-9241
بيانات النشر: Wiley
سنة النشر: 2022
المجموعة: Wiley Online Library (Open Access Articles via Crossref)
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1097/01.hs9.0000846716.90763.d0
DOI: 10.1097/01.HS9.0000846716.90763.d0
الإتاحة: https://doi.org/10.1097/01.hs9.0000846716.90763.d0Test
حقوق: http://creativecommons.org/licenses/by-nc-nd/4.0Test/
رقم الانضمام: edsbas.26D1EB74
قاعدة البيانات: BASE